Bladder cancer
UPDATED --- New hope for patients progressing after prior treatment for mUCa
Objectif pédagogique: Identify appropriate treatment options for patients progressing after prior treatment for metastatic urothelial carcinoma (UCa).
Spécialité: Medical oncology, urology, clinical oncology
Public cible: Specialists (CME: basic, intermediate), Residents (senior)
Dernière mise à jour: October 2024
Contexte:
Regulatory approval status of drugs limited to the metastatic UCa setting (status 1 October 2024)
ChT: chemotherapy; CPS: combined positive score; PD-(L)1: programmed death-(ligand) 1
In all cases presented in this topic, it is assumed that the relevant antibodies/tests are used for PD-L1 and FGFR testing.
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.